###begin article-title 0
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 99 104 <span type="species:ncbi:9606">women</span>
Moderate alcohol consumption increases insulin sensitivity and ADIPOQ expression in postmenopausal women: a randomised, crossover trial
###end article-title 0
###begin title 1
Aims/hypothesis
###end title 1
###begin p 2
###xml 123 129 123 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 216 221 <span type="species:ncbi:9606">women</span>
To determine whether 6 weeks of daily, moderate alcohol consumption increases expression of the gene encoding adiponectin (ADIPOQ) and plasma levels of the protein, and improves insulin sensitivity in postmenopausal women.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 377 383 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 577 583 565 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 112 117 <span type="species:ncbi:9606">women</span>
In a randomised, open-label, crossover trial conducted in the Netherlands, 36 apparently healthy postmenopausal women who were habitual alcohol consumers, received 250 ml white wine (approximately25 g alcohol/day) or 250 ml of white grape juice (control) daily during dinner for 6 weeks. Randomisation to treatment allocation occurred according to BMI. Insulin sensitivity and ADIPOQ mRNA and plasma adiponectin levels were measured at the end of both periods. Insulin sensitivity was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR). Levels of ADIPOQ mRNA in subcutaneous adipose tissue were determined by RT-PCR.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 145 146 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 200 201 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 260 266 250 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 312 313 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 387 388 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 478 479 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 570 576 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 652 655 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#961;</italic>
###xml 664 665 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 711 712 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 755 756 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 819 820 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
All subjects completed the study. Six weeks of white wine consumption reduced fasting insulin (mean +/- SEM 40.0 +/- 3.4 vs 46.5 +/- 3.4 pmol/l; p < 0.01) and HOMA-IR (1.42 +/- 0.13 vs 1.64 +/- 0.13; p = 0.02) compared with 6 weeks of grape juice consumption. ADIPOQ mRNA levels (1.09 +/- 0.15 vs 0.98 +/- 0.15; p = 0.04) and plasma levels of total (13.1 +/- 0.8 vs 12.0 +/- 0.8 mug/ml; p < 0.001) and high molecular weight (HMW) adiponectin (9.9 +/- 1.2 vs 8.8 +/- 1.2 mug/ml; p = 0.02) significantly increased after alcohol compared with juice consumption. Changes in ADIPOQ mRNA levels correlated with changes in plasma levels of total adiponectin (rho = 0.46; p < 0.01). Both fasting triacylglycerol (8.2%; p = 0.04) and LDL-cholesterol levels (7.8%; p < 0.0001) decreased, whereas HDL-cholesterol increased (7.0%; p < 0.0001) after prolonged moderate alcohol intake. No notable adverse effects were reported.
###end p 6
###begin title 7
Conclusions/interpretation
###end title 7
###begin p 8
###xml 126 131 <span type="species:ncbi:9606">women</span>
Moderate alcohol consumption for 6 weeks improves insulin sensitivity, adiponectin levels and lipid profile in postmenopausal women. Furthermore, these data suggest a transcriptional mechanism leading to the alcohol-induced increase in adiponectin plasma levels.
###end p 8
###begin title 9
Trial registration:
###end title 9
###begin p 10
ClinicalTrials.gov ID no.: NCT00285909
###end p 10
###begin title 11
Funding:
###end title 11
###begin p 12
Partly funded by the Dutch Foundation for Alcohol Research (SAR).
###end p 12
###begin title 13
Keywords
###end title 13
###begin title 14
Introduction
###end title 14
###begin p 15
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 508 509 508 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 378 383 <span type="species:ncbi:9606">women</span>
Moderate alcohol consumption has consistently been associated with a decreased risk of type 2 diabetes compared with abstaining and excessive drinking [1, 2]. The reason for the lower risk of type 2 diabetes is not entirely clear but a plausible explanation seems to be improved insulin sensitivity [3]. However, so far only one randomised controlled trial among postmenopausal women has confirmed this notion [4]. Other studies, mainly performed among young male populations, failed to detect such effects [5-12].
###end p 15
###begin p 16
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 637 638 637 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 639 640 639 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
Adiponectin, an adipose tissue-derived hormone, is thought to play an important role in the regulation of insulin sensitivity and glucose and lipid metabolism [13]. Its plasma levels are positively associated with insulin sensitivity [14] and are inversely associated with impaired glucose metabolism and type 2 diabetes [15-17]. Furthermore, observational studies revealed an association between moderate alcohol consumption, adiponectin concentrations and insulin sensitivity [18, 19]. Randomised controlled trials also showed a significant increase in the circulating levels of both total and high molecular weight (HMW) adiponectin [6-8] after a period of moderate alcohol consumption compared with abstention.
###end p 16
###begin p 17
###xml 266 268 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 384 388 376 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLAT</italic>
###xml 434 439 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAI-1</italic>
###xml 454 462 446 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERPINE1</italic>
###xml 465 467 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 576 578 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
However, the mechanism by which moderate alcohol consumption increases adiponectin levels is unknown. Synthesis of adiponectin is controlled by peroxisome proliferator-activated receptor gamma (PPAR-gamma) activation, which functions as a transcriptional regulator [20]. Low doses of alcohol have been shown to alter the expression of the genes encoding tissue plasminogen activator (PLAT) and plasminogen activator inhibitor type-1 (PAI-1 also known as SERPINE1) [21]. Like adiponectin, these markers are affected by moderate alcohol consumption and activated by PPAR-gamma [22].
###end p 17
###begin p 18
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 217 222 <span type="species:ncbi:9606">women</span>
Consequently, we investigated whether moderate alcohol consumption affects expression of the gene encoding adiponectin (ADIPOQ) and levels of the protein, and whether it improves insulin sensitivity in postmenopausal women.
###end p 18
###begin title 19
Methods
###end title 19
###begin p 20
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Study protocol</bold>
###xml 1681 1683 1665 1667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 164 176 <span type="species:ncbi:9606">Participants</span>
###xml 734 746 <span type="species:ncbi:9606">Participants</span>
###xml 1009 1014 <span type="species:ncbi:9606">women</span>
###xml 1081 1086 <span type="species:ncbi:9606">women</span>
Study protocol The study used a randomised, open label, placebo-controlled, crossover design, consisting of two 6 week periods, each preceded by 1 week of washout. Participants consumed 250 ml of white wine (25 g alcohol; Chardonnay; Jean d'Alibert, Rieux, France) or alcohol-free white grape juice (Albert Heijn, Zaandam, the Netherlands) daily for 6 weeks during dinner. The study was conducted at TNO (a Dutch acronym for the Netherlands organisation for applied scientific research) Quality of Life, Zeist, the Netherlands. The primary objective of the study was to investigate the effect of moderate alcohol consumption on PPAR-gamma activity and risk markers of metabolic disease, and it took place between March and June 2006. Participants were instructed to maintain their habitual body weight, food pattern and physical activity pattern and were told to refrain from any alcoholic products during the entire study (including washout periods) except for alcoholic beverages supplied by TNO. Of the 77 women who were screened, 40 were eligible to participate. A total of 36 women were randomly selected and initiated the study. Allocation to treatment order was randomised according to BMI. Both white wine and white grape juice contained 300 kJ/100 ml (approximately70 kcal/100 ml). Blood and adipose tissue sampling was done on the last day of each treatment period after an overnight fast. Compliance was monitored by weekly measurement of urinary ethyl glucuronide (EtG), a direct phase II metabolite of ethanol formed by the action of UDP-glucuronosyl transferase. EtG has been reported to be a superior marker, with 100% sensitivity as a biomarker of recent drinking [23]. It persists in the urine up to approximately75-85 h after the last intake. Additional measures of compliance were an increase in HDL-cholesterol, daily questionnaires, and return of empty bottles.
###end p 20
###begin p 21
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Participants</bold>
###xml 323 324 323 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 28 33 <span type="species:ncbi:9606">women</span>
###xml 152 164 <span type="species:ncbi:9606">participants</span>
###xml 362 374 <span type="species:ncbi:9606">Participants</span>
Participants Postmenopausal women were recruited from a pool of volunteers from TNO Quality of Life and by advertisements in local newspapers. Eligible participants consumed between 5 and 21 units of alcohol per week, were apparently healthy and had an absence of menses for at least 2 years, a BMI between 18.5 and 35 kg/m2 and no family history of alcoholism. Participants gave written informed consent and received compensation for their participation. An independent medical ethics committee (The Medical Ethics Committee of the University Medical Centre Utrecht) approved the research protocol.
###end p 21
###begin p 22
###xml 0 16 0 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Outcome measures</bold>
###xml 233 234 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 305 311 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 465 467 464 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
Outcome measures Primary endpoints were markers of insulin sensitivity, such as homeostasis model assessment of insulin resistance (HOMA-IR), calculated as [fasting serum insulin (in muU/l) x fasting serum glucose (in mmol/l)]/22.5 [5], glucose, insulin, and several adiponectin-related measures, such as ADIPOQ mRNA levels and plasma levels of total and HMW adiponectin. Secondary variables included lipid profile (triacylglycerol and HDL- and LDL-cholesterol) HbA1c and NEFA and correlations between specific outcome measures.
###end p 22
###begin p 23
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Analyses and assessment</bold>
###xml 698 700 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 915 916 914 915 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1029 1030 1028 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 2171 2175 2152 2156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARBP</italic>
###xml 2177 2179 2158 2160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 2221 2227 2202 2208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 2260 2266 2241 2247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 2300 2305 2281 2286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 2337 2342 2318 2323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 2374 2378 2355 2359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARBP</italic>
###xml 2409 2413 2390 2394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARBP</italic>
Analyses and assessment Ethyl glucuronide was determined in morning urine samples. Urinary samples were diluted about 20-fold using an internal standard solution. The resulting solution was analysed using a triple quadrupole Ultra Performance LC/MS in MRM mode (Waters, Saint-Quentin en Yvelines, France) with a detection limit of 50 ng/ml. The cut-off limit to assess compliance during juice intervention for urinary EtG values was set at >0.25 mg/ml (positive sample), to obtain high sensitivity but avoid positive results due to unintentional ethanol exposure. The cut-off limit during wine intervention was set at EtG <0.5 mg/ml (2.2 mumol/l) (negative sample), as proposed by Bottcher et al. [24]. Blood samples were obtained from the antecubital vein of the forearm and collected in tubes containing clot activator for serum and in ice-chilled tubes containing or potassium ethylenediamine tetraacetic acid (K3EDTA) for plasma (Vacutainer Systems, Becton Dickinson, Plymouth, UK). Blood was centrifuged for 15 min at 2,000xg at 4degreesC within 15-30 min after collection and stored at -80degreesC. All biochemical determinations in blood were performed at TNO Quality of Life using Olympus analytical equipment and reagents except for adiponectin. Plasma total adiponectin concentrations were determined by RIA (Linco Research, St Charles, MO, USA) with a mean intra-assay coefficient of variation of 5.0%, and plasma HMW adiponectin levels were determined by a novel ELISA (Linco Research) with a mean intra-assay coefficient of variation of 14.1%. LDL-cholesterol was calculated using the Friedewald formula. Subcutaneous adipose tissue was sampled from the buttock by means of a Strauss cannula, outer diameter 1.5 mm, and stored at -70degreesC until further analysis. Total RNA was extracted from adipose tissue with TRIzol reagent (Invitrogen, Breda, the Netherlands); 1 mg total RNA was then reverse-transcribed with iScript (Bio-Rad, Veenendaal, the Netherlands). cDNA was PCR-amplified with Platinum Taq DNA polymerase (Invitrogen) on an iCycler (Bio-Rad) or MyIQ (Bio-Rad) PCR machine. Expression was standardised to the level of acidic ribosomal protein ARBP [25]. Primer sequences used were as follows: ADIPOQ forward, TATCCCCAACATGCCCATTCG; ADIPOQ reverse, TGGTAGGCAAAGTAGTACAGCC; PPARG forward, TCCATGCTGTTATGGGTGAA; PPARG reverse, TCAAAGGAGTGGGAGTGGTC; ARBP forward, CGGGAAGGCTGTGGTGCTG; ARBP reverse, GTGAACACAAAGCCCACATTCC.
###end p 23
###begin p 24
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Statistical analyses</bold>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 733 739 733 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 795 800 795 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</italic>
###xml 913 914 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Statistical analyses Statistical analyses were performed using the SAS statistical software package (SAS version 8; SAS Institute, Cary, NC, USA). All variables were compared between treatments with a mixed analysis of variance model that included terms for treatment, period and the interaction between period and treatment (indicating possible carryover effects). Body weight was included in the model as a random factor to adjust for changes in body weight. Correlation coefficients were computed according to Spearman rank order to assess associations between intervention-induced changes in outcome measures. Based on a study by Arvidsson et al. [26], a sample size of 36 was considered sufficient to detect a 20% difference in ADIPOQ mRNA levels with a power of 80%, accepting a two-sided alpha of 0.05. Data are presented as mean +/- SEM unless otherwise specified. Statistical significance was defined as p < 0.05.
###end p 24
###begin title 25
Results
###end title 25
###begin p 26
###xml 0 15 0 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink">General results</bold>
###xml 125 126 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 295 296 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 299 306 297 304 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 306 368 304 366 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Characteristics of 36 postmenopausal women before intervention</p>
###xml 306 368 304 366 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">Characteristics of 36 postmenopausal women before intervention</p></caption>
###xml 368 376 366 374 <th xmlns:xlink="http://www.w3.org/1999/xlink">Variable</th>
###xml 376 390 374 388 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Baseline value</th>
###xml 368 390 366 388 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Variable</th><th align="left">Baseline value</th></tr>
###xml 368 390 366 388 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Variable</th><th align="left">Baseline value</th></tr></thead>
###xml 390 401 388 399 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 401 413 399 409 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">56.5&#8201;&#177;&#8201;4.2</td>
###xml 390 413 388 409 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td char="&#177;" align="char">56.5&#8201;&#177;&#8201;4.2</td></tr>
###xml 413 424 409 420 <td xmlns:xlink="http://www.w3.org/1999/xlink">Weight (kg)</td>
###xml 424 437 420 431 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">71.4&#8201;&#177;&#8201;10.0</td>
###xml 413 437 409 431 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Weight (kg)</td><td char="&#177;" align="char">71.4&#8201;&#177;&#8201;10.0</td></tr>
###xml 446 447 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 437 448 431 442 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI (kg/m<sup>2</sup>)</td>
###xml 448 460 442 452 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">25.4&#8201;&#177;&#8201;3.3</td>
###xml 437 460 431 452 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI (kg/m<sup>2</sup>)</td><td char="&#177;" align="char">25.4&#8201;&#177;&#8201;3.3</td></tr>
###xml 460 484 452 476 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fasting glucose (mmol/l)</td>
###xml 484 496 476 486 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.5 &#8201;&#177;&#8201;0.4</td>
###xml 460 496 452 486 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fasting glucose (mmol/l)</td><td char="&#177;" align="char">5.5 &#8201;&#177;&#8201;0.4</td></tr>
###xml 496 520 486 510 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fasting insulin (pmol/l)</td>
###xml 520 533 510 521 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">37.4&#8201;&#177;&#8201;12.6</td>
###xml 496 533 486 521 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fasting insulin (pmol/l)</td><td char="&#177;" align="char">37.4&#8201;&#177;&#8201;12.6</td></tr>
###xml 533 565 521 553 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fasting triacylglycerol (mmol/l)</td>
###xml 565 578 553 564 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.21&#8201;&#177;&#8201;0.54</td>
###xml 533 578 521 564 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fasting triacylglycerol (mmol/l)</td><td char="&#177;" align="char">1.21&#8201;&#177;&#8201;0.54</td></tr>
###xml 578 602 564 588 <td xmlns:xlink="http://www.w3.org/1999/xlink">HDL-cholesterol (mmol/l)</td>
###xml 602 615 588 599 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.67&#8201;&#177;&#8201;0.27</td>
###xml 578 615 564 599 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">1.67&#8201;&#177;&#8201;0.27</td></tr>
###xml 615 639 599 623 <td xmlns:xlink="http://www.w3.org/1999/xlink">LDL-cholesterol (mmol/l)</td>
###xml 639 652 623 634 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">3.88&#8201;&#177;&#8201;0.60</td>
###xml 615 652 599 634 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>LDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">3.88&#8201;&#177;&#8201;0.60</td></tr>
###xml 652 678 634 660 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total cholesterol (mmol/l)</td>
###xml 678 691 660 671 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">6.11&#8201;&#177;&#8201;0.72</td>
###xml 652 691 634 671 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total cholesterol (mmol/l)</td><td char="&#177;" align="char">6.11&#8201;&#177;&#8201;0.72</td></tr>
###xml 691 717 671 697 <td xmlns:xlink="http://www.w3.org/1999/xlink">Alkaline phosphatase (U/l)</td>
###xml 717 730 697 708 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">76.1&#8201;&#177;&#8201;19.3</td>
###xml 691 730 671 708 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Alkaline phosphatase (U/l)</td><td char="&#177;" align="char">76.1&#8201;&#177;&#8201;19.3</td></tr>
###xml 730 760 708 738 <td xmlns:xlink="http://www.w3.org/1999/xlink">Alanine aminotransferase (U/l)</td>
###xml 760 772 738 748 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">15.3&#8201;&#177;&#8201;8.2</td>
###xml 730 772 708 748 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Alanine aminotransferase (U/l)</td><td char="&#177;" align="char">15.3&#8201;&#177;&#8201;8.2</td></tr>
###xml 772 804 748 780 <td xmlns:xlink="http://www.w3.org/1999/xlink">Aspartate aminotransferase (U/l)</td>
###xml 804 816 780 790 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">20.8&#8201;&#177;&#8201;7.4</td>
###xml 772 816 748 790 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Aspartate aminotransferase (U/l)</td><td char="&#177;" align="char">20.8&#8201;&#177;&#8201;7.4</td></tr>
###xml 816 850 790 820 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#947;-Glutamyltranspeptidase (U/l)</td>
###xml 850 863 820 831 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">21.3&#8201;&#177;&#8201;11.4</td>
###xml 816 863 790 831 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#947;-Glutamyltranspeptidase (U/l)</td><td char="&#177;" align="char">21.3&#8201;&#177;&#8201;11.4</td></tr>
###xml 863 898 831 866 <td xmlns:xlink="http://www.w3.org/1999/xlink">Follicle-stimulating hormone (IU/l)</td>
###xml 898 912 866 878 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">108.5&#8201;&#177;&#8201;41.3</td>
###xml 863 912 831 878 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Follicle-stimulating hormone (IU/l)</td><td char="&#177;" align="char">108.5&#8201;&#177;&#8201;41.3</td></tr>
###xml 390 912 388 878 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Age (years)</td><td char="&#177;" align="char">56.5&#8201;&#177;&#8201;4.2</td></tr><tr><td>Weight (kg)</td><td char="&#177;" align="char">71.4&#8201;&#177;&#8201;10.0</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td char="&#177;" align="char">25.4&#8201;&#177;&#8201;3.3</td></tr><tr><td>Fasting glucose (mmol/l)</td><td char="&#177;" align="char">5.5 &#8201;&#177;&#8201;0.4</td></tr><tr><td>Fasting insulin (pmol/l)</td><td char="&#177;" align="char">37.4&#8201;&#177;&#8201;12.6</td></tr><tr><td>Fasting triacylglycerol (mmol/l)</td><td char="&#177;" align="char">1.21&#8201;&#177;&#8201;0.54</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">1.67&#8201;&#177;&#8201;0.27</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">3.88&#8201;&#177;&#8201;0.60</td></tr><tr><td>Total cholesterol (mmol/l)</td><td char="&#177;" align="char">6.11&#8201;&#177;&#8201;0.72</td></tr><tr><td>Alkaline phosphatase (U/l)</td><td char="&#177;" align="char">76.1&#8201;&#177;&#8201;19.3</td></tr><tr><td>Alanine aminotransferase (U/l)</td><td char="&#177;" align="char">15.3&#8201;&#177;&#8201;8.2</td></tr><tr><td>Aspartate aminotransferase (U/l)</td><td char="&#177;" align="char">20.8&#8201;&#177;&#8201;7.4</td></tr><tr><td>&#947;-Glutamyltranspeptidase (U/l)</td><td char="&#177;" align="char">21.3&#8201;&#177;&#8201;11.4</td></tr><tr><td>Follicle-stimulating hormone (IU/l)</td><td char="&#177;" align="char">108.5&#8201;&#177;&#8201;41.3</td></tr></tbody>
###xml 368 912 366 878 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Variable</th><th align="left">Baseline value</th></tr></thead><tbody><tr><td>Age (years)</td><td char="&#177;" align="char">56.5&#8201;&#177;&#8201;4.2</td></tr><tr><td>Weight (kg)</td><td char="&#177;" align="char">71.4&#8201;&#177;&#8201;10.0</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td char="&#177;" align="char">25.4&#8201;&#177;&#8201;3.3</td></tr><tr><td>Fasting glucose (mmol/l)</td><td char="&#177;" align="char">5.5 &#8201;&#177;&#8201;0.4</td></tr><tr><td>Fasting insulin (pmol/l)</td><td char="&#177;" align="char">37.4&#8201;&#177;&#8201;12.6</td></tr><tr><td>Fasting triacylglycerol (mmol/l)</td><td char="&#177;" align="char">1.21&#8201;&#177;&#8201;0.54</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">1.67&#8201;&#177;&#8201;0.27</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">3.88&#8201;&#177;&#8201;0.60</td></tr><tr><td>Total cholesterol (mmol/l)</td><td char="&#177;" align="char">6.11&#8201;&#177;&#8201;0.72</td></tr><tr><td>Alkaline phosphatase (U/l)</td><td char="&#177;" align="char">76.1&#8201;&#177;&#8201;19.3</td></tr><tr><td>Alanine aminotransferase (U/l)</td><td char="&#177;" align="char">15.3&#8201;&#177;&#8201;8.2</td></tr><tr><td>Aspartate aminotransferase (U/l)</td><td char="&#177;" align="char">20.8&#8201;&#177;&#8201;7.4</td></tr><tr><td>&#947;-Glutamyltranspeptidase (U/l)</td><td char="&#177;" align="char">21.3&#8201;&#177;&#8201;11.4</td></tr><tr><td>Follicle-stimulating hormone (IU/l)</td><td char="&#177;" align="char">108.5&#8201;&#177;&#8201;41.3</td></tr></tbody></table>
###xml 912 932 878 896 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Data are mean&#8201;&#177;&#8201;SD</p>
###xml 912 932 878 896 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Data are mean&#8201;&#177;&#8201;SD</p></table-wrap-foot>
###xml 299 932 297 896 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="27">Characteristics of 36 postmenopausal women before intervention</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th align="left">Baseline value</th></tr></thead><tbody><tr><td>Age (years)</td><td char="&#177;" align="char">56.5&#8201;&#177;&#8201;4.2</td></tr><tr><td>Weight (kg)</td><td char="&#177;" align="char">71.4&#8201;&#177;&#8201;10.0</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td char="&#177;" align="char">25.4&#8201;&#177;&#8201;3.3</td></tr><tr><td>Fasting glucose (mmol/l)</td><td char="&#177;" align="char">5.5 &#8201;&#177;&#8201;0.4</td></tr><tr><td>Fasting insulin (pmol/l)</td><td char="&#177;" align="char">37.4&#8201;&#177;&#8201;12.6</td></tr><tr><td>Fasting triacylglycerol (mmol/l)</td><td char="&#177;" align="char">1.21&#8201;&#177;&#8201;0.54</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">1.67&#8201;&#177;&#8201;0.27</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">3.88&#8201;&#177;&#8201;0.60</td></tr><tr><td>Total cholesterol (mmol/l)</td><td char="&#177;" align="char">6.11&#8201;&#177;&#8201;0.72</td></tr><tr><td>Alkaline phosphatase (U/l)</td><td char="&#177;" align="char">76.1&#8201;&#177;&#8201;19.3</td></tr><tr><td>Alanine aminotransferase (U/l)</td><td char="&#177;" align="char">15.3&#8201;&#177;&#8201;8.2</td></tr><tr><td>Aspartate aminotransferase (U/l)</td><td char="&#177;" align="char">20.8&#8201;&#177;&#8201;7.4</td></tr><tr><td>&#947;-Glutamyltranspeptidase (U/l)</td><td char="&#177;" align="char">21.3&#8201;&#177;&#8201;11.4</td></tr><tr><td>Follicle-stimulating hormone (IU/l)</td><td char="&#177;" align="char">108.5&#8201;&#177;&#8201;41.3</td></tr></tbody></table><table-wrap-foot><p textid="28">Data are mean&#8201;&#177;&#8201;SD</p></table-wrap-foot></table-wrap>
###xml 38 43 <span type="species:ncbi:9606">women</span>
###xml 65 77 <span type="species:ncbi:9606">Participants</span>
###xml 238 250 <span type="species:ncbi:9606">participants</span>
###xml 343 348 <span type="species:ncbi:9606">women</span>
General results All 36 postmenopausal women completed the study. Participants were slightly overweight (BMI 25.4 +/- 3.3 kg/m2). Mean glucose, insulin, triacylglycerol and cholesterol concentrations before the intervention indicated that participants were euglycaemic and normolipidaemic (Table 1). Table 1Characteristics of 36 postmenopausal women before interventionVariableBaseline valueAge (years)56.5 +/- 4.2Weight (kg)71.4 +/- 10.0BMI (kg/m2)25.4 +/- 3.3Fasting glucose (mmol/l)5.5  +/- 0.4Fasting insulin (pmol/l)37.4 +/- 12.6Fasting triacylglycerol (mmol/l)1.21 +/- 0.54HDL-cholesterol (mmol/l)1.67 +/- 0.27LDL-cholesterol (mmol/l)3.88 +/- 0.60Total cholesterol (mmol/l)6.11 +/- 0.72Alkaline phosphatase (U/l)76.1 +/- 19.3Alanine aminotransferase (U/l)15.3 +/- 8.2Aspartate aminotransferase (U/l)20.8 +/- 7.4gamma-Glutamyltranspeptidase (U/l)21.3 +/- 11.4Follicle-stimulating hormone (IU/l)108.5 +/- 41.3Data are mean +/- SD
###end p 26
###begin p 27
###xml 37 42 <span type="species:ncbi:9606">women</span>
Characteristics of 36 postmenopausal women before intervention
###end p 27
###begin p 28
Data are mean +/- SD
###end p 28
###begin p 29
###xml 399 400 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 403 410 403 410 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 410 582 410 582 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Markers of insulin sensitivity, adiponectin and lipid profile in 36 postmenopausal women measured at the end of a 6&#160;week period of consuming white grape juice or white wine</p>
###xml 410 582 410 582 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Markers of insulin sensitivity, adiponectin and lipid profile in 36 postmenopausal women measured at the end of a 6&#160;week period of consuming white grape juice or white wine</p></caption>
###xml 582 590 582 590 <th xmlns:xlink="http://www.w3.org/1999/xlink">Variable</th>
###xml 590 601 590 601 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Grape juice</th>
###xml 601 611 601 611 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">White wine</th>
###xml 611 612 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 611 618 611 618 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic> value</th>
###xml 582 618 582 618 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Variable</th><th align="left">Grape juice</th><th align="left">White wine</th><th align="left"><italic>p</italic> value</th></tr>
###xml 582 618 582 618 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Variable</th><th align="left">Grape juice</th><th align="left">White wine</th><th align="left"><italic>p</italic> value</th></tr></thead>
###xml 618 637 618 637 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Insulin sensitivity</td>
###xml 618 637 618 637 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Insulin sensitivity</td></tr>
###xml 637 644 637 644 <td xmlns:xlink="http://www.w3.org/1999/xlink">HOMA-IR</td>
###xml 644 657 644 655 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.64&#8201;&#177;&#8201;0.13</td>
###xml 657 670 655 666 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.42&#8201;&#177;&#8201;0.13</td>
###xml 670 674 666 670 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 637 674 637 670 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HOMA-IR</td><td char="&#177;" align="char">1.64&#8201;&#177;&#8201;0.13</td><td char="&#177;" align="char">1.42&#8201;&#177;&#8201;0.13</td><td char="." align="char">0.02</td></tr>
###xml 674 698 670 694 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fasting insulin (pmol/l)</td>
###xml 698 710 694 704 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">46.5&#8201;&#177;&#8201;3.4</td>
###xml 710 722 704 714 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">40.0&#8201;&#177;&#8201;3.4</td>
###xml 722 727 714 719 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.01</td>
###xml 674 727 670 719 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fasting insulin (pmol/l)</td><td char="&#177;" align="char">46.5&#8201;&#177;&#8201;3.4</td><td char="&#177;" align="char">40.0&#8201;&#177;&#8201;3.4</td><td char="." align="char">&lt;0.01</td></tr>
###xml 727 751 719 743 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fasting glucose (mmol/l)</td>
###xml 751 762 743 752 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.4&#8201;&#177;&#8201;0.1</td>
###xml 762 773 752 761 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.4&#8201;&#177;&#8201;0.1</td>
###xml 773 777 761 765 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.72</td>
###xml 727 777 719 765 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fasting glucose (mmol/l)</td><td char="&#177;" align="char">5.4&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">5.4&#8201;&#177;&#8201;0.1</td><td char="." align="char">0.72</td></tr>
###xml 780 782 768 770 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 777 786 765 774 <td xmlns:xlink="http://www.w3.org/1999/xlink">HbA<sub>1c</sub> (%)</td>
###xml 786 798 774 784 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">6.0&#8201;&#177;&#8201;0.04</td>
###xml 798 810 784 794 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.9&#8201;&#177;&#8201;0.04</td>
###xml 810 814 794 798 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.09</td>
###xml 777 814 765 798 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HbA<sub>1c</sub> (%)</td><td char="&#177;" align="char">6.0&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">5.9&#8201;&#177;&#8201;0.04</td><td char="." align="char">0.09</td></tr>
###xml 814 835 798 819 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fasting NEFA (mmol/l)</td>
###xml 835 849 819 831 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.43&#8201;&#177;&#8201; 0.04</td>
###xml 849 862 831 842 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.44&#8201;&#177;&#8201;0.04</td>
###xml 862 866 842 846 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.67</td>
###xml 814 866 798 846 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fasting NEFA (mmol/l)</td><td char="&#177;" align="char">0.43&#8201;&#177;&#8201; 0.04</td><td char="&#177;" align="char">0.44&#8201;&#177;&#8201;0.04</td><td char="." align="char">0.67</td></tr>
###xml 866 882 846 862 <td xmlns:xlink="http://www.w3.org/1999/xlink">Body weight (kg)</td>
###xml 882 894 862 872 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">70.4&#8201;&#177;&#8201;1.7</td>
###xml 894 906 872 882 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">71.1&#8201;&#177;&#8201;1.7</td>
###xml 906 912 882 888 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 866 912 846 888 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Body weight (kg)</td><td char="&#177;" align="char">70.4&#8201;&#177;&#8201;1.7</td><td char="&#177;" align="char">71.1&#8201;&#177;&#8201;1.7</td><td char="." align="char">&lt;0.001</td></tr>
###xml 912 923 888 899 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Adiponectin</td>
###xml 912 923 888 899 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Adiponectin</td></tr>
###xml 923 929 899 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 930 934 906 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARBP</italic>
###xml 923 957 899 933 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ADIPOQ</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td>
###xml 957 970 933 944 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.98&#8201;&#177;&#8201;0.15</td>
###xml 970 983 944 955 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.09&#8201;&#177;&#8201;0.15</td>
###xml 983 987 955 959 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.04</td>
###xml 923 987 899 959 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>ADIPOQ</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#177;" align="char">0.98&#8201;&#177;&#8201;0.15</td><td char="&#177;" align="char">1.09&#8201;&#177;&#8201;0.15</td><td char="." align="char">0.04</td></tr>
###xml 987 992 959 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 993 997 965 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARBP</italic>
###xml 987 1020 959 992 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PPARG</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td>
###xml 1020 1033 992 1003 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.67&#8201;&#177;&#8201;0.09</td>
###xml 1033 1046 1003 1014 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.73&#8201;&#177;&#8201;0.09</td>
###xml 1046 1050 1014 1018 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.13</td>
###xml 987 1050 959 1018 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>PPARG</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#177;" align="char">0.67&#8201;&#177;&#8201;0.09</td><td char="&#177;" align="char">0.73&#8201;&#177;&#8201;0.09</td><td char="." align="char">0.13</td></tr>
###xml 1050 1084 1018 1051 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fasting total adiponectin (&#956;g/ml)</td>
###xml 1084 1096 1051 1061 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">12.0&#8201;&#177;&#8201;0.8</td>
###xml 1096 1108 1061 1071 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">13.1&#8201;&#177;&#8201;0.8</td>
###xml 1108 1114 1071 1077 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1050 1114 1018 1077 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fasting total adiponectin (&#956;g/ml)</td><td char="&#177;" align="char">12.0&#8201;&#177;&#8201;0.8</td><td char="&#177;" align="char">13.1&#8201;&#177;&#8201;0.8</td><td char="." align="char">&lt;0.001</td></tr>
###xml 1114 1146 1077 1108 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fasting HMW adiponectin (&#956;g/ml)</td>
###xml 1146 1157 1108 1117 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">8.8&#8201;&#177;&#8201;1.2</td>
###xml 1157 1168 1117 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">9.9&#8201;&#177;&#8201;1.2</td>
###xml 1168 1172 1126 1130 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 1114 1172 1077 1130 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fasting HMW adiponectin (&#956;g/ml)</td><td char="&#177;" align="char">8.8&#8201;&#177;&#8201;1.2</td><td char="&#177;" align="char">9.9&#8201;&#177;&#8201;1.2</td><td char="." align="char">0.02</td></tr>
###xml 1172 1185 1130 1143 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Lipid profile</td>
###xml 1172 1185 1130 1143 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Lipid profile</td></tr>
###xml 1185 1217 1143 1175 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fasting triacylglycerol (mmol/l)</td>
###xml 1217 1230 1175 1186 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.18&#8201;&#177;&#8201;0.08</td>
###xml 1230 1243 1186 1197 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.03&#8201;&#177;&#8201;0.08</td>
###xml 1243 1247 1197 1201 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.04</td>
###xml 1185 1247 1143 1201 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fasting triacylglycerol (mmol/l)</td><td char="&#177;" align="char">1.18&#8201;&#177;&#8201;0.08</td><td char="&#177;" align="char">1.03&#8201;&#177;&#8201;0.08</td><td char="." align="char">0.04</td></tr>
###xml 1247 1271 1201 1225 <td xmlns:xlink="http://www.w3.org/1999/xlink">HDL-cholesterol (mmol/l)</td>
###xml 1271 1284 1225 1236 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.57&#8201;&#177;&#8201;0.04</td>
###xml 1284 1297 1236 1247 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.68&#8201;&#177;&#8201;0.04</td>
###xml 1297 1304 1247 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1247 1304 1201 1254 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">1.57&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">1.68&#8201;&#177;&#8201;0.04</td><td char="." align="char">&lt;0.0001</td></tr>
###xml 1304 1328 1254 1278 <td xmlns:xlink="http://www.w3.org/1999/xlink">LDL-cholesterol (mmol/l)</td>
###xml 1328 1341 1278 1289 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">3.84&#8201;&#177;&#8201;0.12</td>
###xml 1341 1354 1289 1300 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">3.51&#8201;&#177;&#8201;0.12</td>
###xml 1354 1361 1300 1307 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1304 1361 1254 1307 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>LDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">3.84&#8201;&#177;&#8201;0.12</td><td char="&#177;" align="char">3.51&#8201;&#177;&#8201;0.12</td><td char="." align="char">&lt;0.0001</td></tr>
###xml 618 1361 618 1307 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="4">Insulin sensitivity</td></tr><tr><td>HOMA-IR</td><td char="&#177;" align="char">1.64&#8201;&#177;&#8201;0.13</td><td char="&#177;" align="char">1.42&#8201;&#177;&#8201;0.13</td><td char="." align="char">0.02</td></tr><tr><td>Fasting insulin (pmol/l)</td><td char="&#177;" align="char">46.5&#8201;&#177;&#8201;3.4</td><td char="&#177;" align="char">40.0&#8201;&#177;&#8201;3.4</td><td char="." align="char">&lt;0.01</td></tr><tr><td>Fasting glucose (mmol/l)</td><td char="&#177;" align="char">5.4&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">5.4&#8201;&#177;&#8201;0.1</td><td char="." align="char">0.72</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td char="&#177;" align="char">6.0&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">5.9&#8201;&#177;&#8201;0.04</td><td char="." align="char">0.09</td></tr><tr><td>Fasting NEFA (mmol/l)</td><td char="&#177;" align="char">0.43&#8201;&#177;&#8201; 0.04</td><td char="&#177;" align="char">0.44&#8201;&#177;&#8201;0.04</td><td char="." align="char">0.67</td></tr><tr><td>Body weight (kg)</td><td char="&#177;" align="char">70.4&#8201;&#177;&#8201;1.7</td><td char="&#177;" align="char">71.1&#8201;&#177;&#8201;1.7</td><td char="." align="char">&lt;0.001</td></tr><tr><td colspan="4">Adiponectin</td></tr><tr><td><italic>ADIPOQ</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#177;" align="char">0.98&#8201;&#177;&#8201;0.15</td><td char="&#177;" align="char">1.09&#8201;&#177;&#8201;0.15</td><td char="." align="char">0.04</td></tr><tr><td><italic>PPARG</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#177;" align="char">0.67&#8201;&#177;&#8201;0.09</td><td char="&#177;" align="char">0.73&#8201;&#177;&#8201;0.09</td><td char="." align="char">0.13</td></tr><tr><td>Fasting total adiponectin (&#956;g/ml)</td><td char="&#177;" align="char">12.0&#8201;&#177;&#8201;0.8</td><td char="&#177;" align="char">13.1&#8201;&#177;&#8201;0.8</td><td char="." align="char">&lt;0.001</td></tr><tr><td>Fasting HMW adiponectin (&#956;g/ml)</td><td char="&#177;" align="char">8.8&#8201;&#177;&#8201;1.2</td><td char="&#177;" align="char">9.9&#8201;&#177;&#8201;1.2</td><td char="." align="char">0.02</td></tr><tr><td colspan="4">Lipid profile</td></tr><tr><td>Fasting triacylglycerol (mmol/l)</td><td char="&#177;" align="char">1.18&#8201;&#177;&#8201;0.08</td><td char="&#177;" align="char">1.03&#8201;&#177;&#8201;0.08</td><td char="." align="char">0.04</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">1.57&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">1.68&#8201;&#177;&#8201;0.04</td><td char="." align="char">&lt;0.0001</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">3.84&#8201;&#177;&#8201;0.12</td><td char="&#177;" align="char">3.51&#8201;&#177;&#8201;0.12</td><td char="." align="char">&lt;0.0001</td></tr></tbody>
###xml 582 1361 582 1307 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Variable</th><th align="left">Grape juice</th><th align="left">White wine</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Insulin sensitivity</td></tr><tr><td>HOMA-IR</td><td char="&#177;" align="char">1.64&#8201;&#177;&#8201;0.13</td><td char="&#177;" align="char">1.42&#8201;&#177;&#8201;0.13</td><td char="." align="char">0.02</td></tr><tr><td>Fasting insulin (pmol/l)</td><td char="&#177;" align="char">46.5&#8201;&#177;&#8201;3.4</td><td char="&#177;" align="char">40.0&#8201;&#177;&#8201;3.4</td><td char="." align="char">&lt;0.01</td></tr><tr><td>Fasting glucose (mmol/l)</td><td char="&#177;" align="char">5.4&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">5.4&#8201;&#177;&#8201;0.1</td><td char="." align="char">0.72</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td char="&#177;" align="char">6.0&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">5.9&#8201;&#177;&#8201;0.04</td><td char="." align="char">0.09</td></tr><tr><td>Fasting NEFA (mmol/l)</td><td char="&#177;" align="char">0.43&#8201;&#177;&#8201; 0.04</td><td char="&#177;" align="char">0.44&#8201;&#177;&#8201;0.04</td><td char="." align="char">0.67</td></tr><tr><td>Body weight (kg)</td><td char="&#177;" align="char">70.4&#8201;&#177;&#8201;1.7</td><td char="&#177;" align="char">71.1&#8201;&#177;&#8201;1.7</td><td char="." align="char">&lt;0.001</td></tr><tr><td colspan="4">Adiponectin</td></tr><tr><td><italic>ADIPOQ</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#177;" align="char">0.98&#8201;&#177;&#8201;0.15</td><td char="&#177;" align="char">1.09&#8201;&#177;&#8201;0.15</td><td char="." align="char">0.04</td></tr><tr><td><italic>PPARG</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#177;" align="char">0.67&#8201;&#177;&#8201;0.09</td><td char="&#177;" align="char">0.73&#8201;&#177;&#8201;0.09</td><td char="." align="char">0.13</td></tr><tr><td>Fasting total adiponectin (&#956;g/ml)</td><td char="&#177;" align="char">12.0&#8201;&#177;&#8201;0.8</td><td char="&#177;" align="char">13.1&#8201;&#177;&#8201;0.8</td><td char="." align="char">&lt;0.001</td></tr><tr><td>Fasting HMW adiponectin (&#956;g/ml)</td><td char="&#177;" align="char">8.8&#8201;&#177;&#8201;1.2</td><td char="&#177;" align="char">9.9&#8201;&#177;&#8201;1.2</td><td char="." align="char">0.02</td></tr><tr><td colspan="4">Lipid profile</td></tr><tr><td>Fasting triacylglycerol (mmol/l)</td><td char="&#177;" align="char">1.18&#8201;&#177;&#8201;0.08</td><td char="&#177;" align="char">1.03&#8201;&#177;&#8201;0.08</td><td char="." align="char">0.04</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">1.57&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">1.68&#8201;&#177;&#8201;0.04</td><td char="." align="char">&lt;0.0001</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">3.84&#8201;&#177;&#8201;0.12</td><td char="&#177;" align="char">3.51&#8201;&#177;&#8201;0.12</td><td char="." align="char">&lt;0.0001</td></tr></tbody></table>
###xml 1361 1382 1307 1326 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Data are mean&#8201;&#177;&#8201;SEM</p>
###xml 1361 1382 1307 1326 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Data are mean&#8201;&#177;&#8201;SEM</p></table-wrap-foot>
###xml 403 1382 403 1326 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="30">Markers of insulin sensitivity, adiponectin and lipid profile in 36 postmenopausal women measured at the end of a 6&#160;week period of consuming white grape juice or white wine</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th align="left">Grape juice</th><th align="left">White wine</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Insulin sensitivity</td></tr><tr><td>HOMA-IR</td><td char="&#177;" align="char">1.64&#8201;&#177;&#8201;0.13</td><td char="&#177;" align="char">1.42&#8201;&#177;&#8201;0.13</td><td char="." align="char">0.02</td></tr><tr><td>Fasting insulin (pmol/l)</td><td char="&#177;" align="char">46.5&#8201;&#177;&#8201;3.4</td><td char="&#177;" align="char">40.0&#8201;&#177;&#8201;3.4</td><td char="." align="char">&lt;0.01</td></tr><tr><td>Fasting glucose (mmol/l)</td><td char="&#177;" align="char">5.4&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">5.4&#8201;&#177;&#8201;0.1</td><td char="." align="char">0.72</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td char="&#177;" align="char">6.0&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">5.9&#8201;&#177;&#8201;0.04</td><td char="." align="char">0.09</td></tr><tr><td>Fasting NEFA (mmol/l)</td><td char="&#177;" align="char">0.43&#8201;&#177;&#8201; 0.04</td><td char="&#177;" align="char">0.44&#8201;&#177;&#8201;0.04</td><td char="." align="char">0.67</td></tr><tr><td>Body weight (kg)</td><td char="&#177;" align="char">70.4&#8201;&#177;&#8201;1.7</td><td char="&#177;" align="char">71.1&#8201;&#177;&#8201;1.7</td><td char="." align="char">&lt;0.001</td></tr><tr><td colspan="4">Adiponectin</td></tr><tr><td><italic>ADIPOQ</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#177;" align="char">0.98&#8201;&#177;&#8201;0.15</td><td char="&#177;" align="char">1.09&#8201;&#177;&#8201;0.15</td><td char="." align="char">0.04</td></tr><tr><td><italic>PPARG</italic>/<italic>ARBP</italic> mRNA (arbitrary units)</td><td char="&#177;" align="char">0.67&#8201;&#177;&#8201;0.09</td><td char="&#177;" align="char">0.73&#8201;&#177;&#8201;0.09</td><td char="." align="char">0.13</td></tr><tr><td>Fasting total adiponectin (&#956;g/ml)</td><td char="&#177;" align="char">12.0&#8201;&#177;&#8201;0.8</td><td char="&#177;" align="char">13.1&#8201;&#177;&#8201;0.8</td><td char="." align="char">&lt;0.001</td></tr><tr><td>Fasting HMW adiponectin (&#956;g/ml)</td><td char="&#177;" align="char">8.8&#8201;&#177;&#8201;1.2</td><td char="&#177;" align="char">9.9&#8201;&#177;&#8201;1.2</td><td char="." align="char">0.02</td></tr><tr><td colspan="4">Lipid profile</td></tr><tr><td>Fasting triacylglycerol (mmol/l)</td><td char="&#177;" align="char">1.18&#8201;&#177;&#8201;0.08</td><td char="&#177;" align="char">1.03&#8201;&#177;&#8201;0.08</td><td char="." align="char">0.04</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">1.57&#8201;&#177;&#8201;0.04</td><td char="&#177;" align="char">1.68&#8201;&#177;&#8201;0.04</td><td char="." align="char">&lt;0.0001</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td char="&#177;" align="char">3.84&#8201;&#177;&#8201;0.12</td><td char="&#177;" align="char">3.51&#8201;&#177;&#8201;0.12</td><td char="." align="char">&lt;0.0001</td></tr></tbody></table><table-wrap-foot><p textid="31">Data are mean&#8201;&#177;&#8201;SEM</p></table-wrap-foot></table-wrap>
###xml 493 498 <span type="species:ncbi:9606">women</span>
Compliance with treatments was assessed by weekly urinary EtG, revealing two positive samples during the juice-drinking period and six negative samples during the wine-drinking period out of the 468 samples analysed (overall compliance 98.3%). Another indicator of compliance was the 7.0% higher level of HDL-cholesterol after wine consumption compared with the value after juice consumption (Table 2). Table 2Markers of insulin sensitivity, adiponectin and lipid profile in 36 postmenopausal women measured at the end of a 6 week period of consuming white grape juice or white wineVariableGrape juiceWhite winep valueInsulin sensitivityHOMA-IR1.64 +/- 0.131.42 +/- 0.130.02Fasting insulin (pmol/l)46.5 +/- 3.440.0 +/- 3.4<0.01Fasting glucose (mmol/l)5.4 +/- 0.15.4 +/- 0.10.72HbA1c (%)6.0 +/- 0.045.9 +/- 0.040.09Fasting NEFA (mmol/l)0.43 +/-  0.040.44 +/- 0.040.67Body weight (kg)70.4 +/- 1.771.1 +/- 1.7<0.001AdiponectinADIPOQ/ARBP mRNA (arbitrary units)0.98 +/- 0.151.09 +/- 0.150.04PPARG/ARBP mRNA (arbitrary units)0.67 +/- 0.090.73 +/- 0.090.13Fasting total adiponectin (mug/ml)12.0 +/- 0.813.1 +/- 0.8<0.001Fasting HMW adiponectin (mug/ml)8.8 +/- 1.29.9 +/- 1.20.02Lipid profileFasting triacylglycerol (mmol/l)1.18 +/- 0.081.03 +/- 0.080.04HDL-cholesterol (mmol/l)1.57 +/- 0.041.68 +/- 0.04<0.0001LDL-cholesterol (mmol/l)3.84 +/- 0.123.51 +/- 0.12<0.0001Data are mean +/- SEM
###end p 29
###begin p 30
###xml 83 88 <span type="species:ncbi:9606">women</span>
Markers of insulin sensitivity, adiponectin and lipid profile in 36 postmenopausal women measured at the end of a 6 week period of consuming white grape juice or white wine
###end p 30
###begin p 31
Data are mean +/- SEM
###end p 31
###begin p 32
###xml 16 17 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 486 487 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
No significant (p > 0.05) carryover effects, as assessed by interaction between treatment and period effects, were observed for any outcome measures. Treatment means of variables and p values estimated from models with period effects were very similar to those obtained from models without a period effect, and we report the results of the latter. Mean body weight was 0.7 kg higher (p < 0.001) at the end of the wine-drinking period than at the end of the juice-drinking period (Table 2). Results were adjusted for this difference in body weight but did not essentially change them. Therefore, unadjusted results are presented here.
###end p 32
###begin p 33
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Insulin sensitivity</bold>
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 98 100 98 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 535 536 535 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
Insulin sensitivity Fasting serum insulin concentration was lower (by 12.3%; p < 0.01) and the HbA1c percentage tended to be lower (p = 0.09) after 6 weeks of moderate alcohol consumption than after 6 weeks of abstention. Insulin sensitivity, as expressed by the HOMA-IR index, improved by 11.9% (p = 0.02) after white wine consumption compared with that following juice consumption. However, serum glucose and NEFA concentrations did not differ significantly between the two interventions at the end of the intervention period (Table 2).
###end p 33
###begin p 34
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Adiponectin</bold>
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 119 120 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARBP</italic>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 419 420 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 458 459 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 558 559 558 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 132 137 <span type="species:ncbi:9606">women</span>
Adiponectin There was a significant increase in the relative ADIPOQ mRNA levels in subcutaneous adipose tissue (27.7%; p = 0.04) of women who consumed alcohol in moderation for 6 weeks compared with those who consumed juice. Consistently, the ratio of PPARG/ARBP mRNA levels also tended to increase, although not significantly (p = 0.13), after the alcohol treatment. Plasma protein levels of total adiponectin (10.6%; p < 0.001) and HMW adiponectin (15.8%; p = 0.02) increased significantly after consuming white wine, rather than juice, for 6 weeks (Table 2).
###end p 34
###begin p 35
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Lipid profile</bold>
###xml 173 174 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
Lipid profile Besides a significant increase in HDL-cholesterol, changes in lipid profile were further characterised by significantly lower levels of LDL-cholesterol (7.8%; p < 0.001) and triacylglycerol (8.2%; p = 0.04) after the wine-drinking period compared with the juice-drinking period (Table 2).
###end p 35
###begin p 36
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Correlations</bold>
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 139 140 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 229 230 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 311 312 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 451 452 443 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 494 495 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 617 618 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 664 667 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#961;</italic>
###xml 676 677 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Correlations Changes in ADIPOQ mRNA levels due to alcohol consumption correlated positively with changes in PPARG mRNA levels (rho = 0.76; p < 0.001) and with changes in the plasma protein level of total adiponectin (rho = 0.46; p < 0.01), but not with changes in plasma levels of HMW adiponectin (rho = -0.25; p = 0.15). No significant correlations were found between changes in HOMA-IR and changes in plasma levels of total adiponectin (rho = 0.27; p = 0.11) or HMW adiponectin (rho = -0.18; p = 0.29). Furthermore, changes in HDL-cholesterol correlated significantly with changes in total adiponectin (rho = 0.47; p < 0.01) but not with HMW adiponectin levels (rho = 0.13; p = 0.44).
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 331 337 331 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 140 145 <span type="species:ncbi:9606">women</span>
###xml 688 693 <span type="species:ncbi:9606">women</span>
The primary findings of this study are that daily, moderate alcohol intake improves insulin sensitivity and lipid profile in postmenopausal women. Furthermore, ADIPOQ mRNA levels in subcutaneous adipose tissue along with plasma levels of total and HMW adiponectin increased after moderate alcohol consumption. Moreover, changes in ADIPOQ mRNA levels correlated with changes in plasma total adiponectin, indicating that prolonged moderate alcohol intake increases circulating adiponectin through increased gene expression. However, improvements in insulin sensitivity were not associated with increased plasma adiponectin levels (HMW and total) after moderate alcohol consumption in these women.
###end p 38
###begin p 39
###xml 645 651 645 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 691 697 691 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 930 936 930 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 825 837 <span type="species:ncbi:9606">participants</span>
###xml 863 868 <span type="species:ncbi:9606">human</span>
A strength of this study is its randomised crossover design. Another strength is that we assessed compliance to study treatment several times in different ways throughout the study and observed no significant deviations. Several limitations warrant consideration. A slightly lower body weight was observed after the juice intervention compared with the alcohol intervention. However, lower body weight is associated with improved insulin sensitivity and thus could have only affected the results towards no alcohol-induced improvement in insulin sensitivity. In the present study, only subcutaneous adipose tissue samples were used to determine ADIPOQ mRNA levels. Studies demonstrated that ADIPOQ mRNA levels were higher [27, 28] or not different [29] in subcutaneous compared with visceral adipose tissue in lean and obese participants. Furthermore, studies in human adipose tissue showed increased [30] as well as similar [31] ADIPOQ mRNA and in vitro adiponectin secretion levels from subcutaneous compared with omental adipocytes. Subcutaneous adipose tissue thus appears to be at least as important as omental adipose tissue for circulating plasma adiponectin levels.
###end p 39
###begin p 40
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 528 529 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 579 580 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 606 607 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 842 843 842 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 876 877 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 1222 1223 1222 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1225 1227 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1244 1245 1244 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1246 1247 1246 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1248 1250 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1344 1345 1344 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1364 1366 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 1789 1790 1789 1790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 2015 2017 2015 2017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 2210 2212 2210 2212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 192 197 <span type="species:ncbi:9606">women</span>
###xml 891 897 <span type="species:ncbi:9606">people</span>
###xml 1010 1016 <span type="species:ncbi:9606">people</span>
###xml 1099 1105 <span type="species:ncbi:9606">people</span>
###xml 1727 1732 <span type="species:ncbi:9606">women</span>
###xml 1741 1744 <span type="species:ncbi:9606">men</span>
The observed changes in insulin sensitivity after prolonged moderate alcohol intake are in accordance with a study by Davies et al. [4] in which moderate alcohol consumption in postmenopausal women for 8 weeks decreased fasting insulin and triacylglycerol levels-both independent risk factors for type 2 diabetes-and improved insulin sensitivity. However, other clinical trials did not find a change in fasting insulin levels [9] and triacylglycerol levels [32, 33] or in insulin sensitivity after moderate alcohol consumption [5-8, 10, 11], whereas levels of total adiponectin [6, 7] and HMW adiponectin [8] did increase. Differences in the designs used in these clinical trials are numerous. However, studies that did observe an effect on markers of insulin sensitivity after moderate alcohol consumption were all performed in middle-aged [4], relatively insulin-resistant [6] or diabetic people [34, 35]. This suggests that the effect of moderate alcohol intake on insulin sensitivity is more pronounced in people with (slightly) impaired glucose tolerance rather than young and glucose-tolerant people. Moreover, most interventions that did not observe a link between alcohol and insulin sensitivity involved only 30 [5, 12] or even fewer [6-8,11] days of consecutive alcohol consumption, while this study and the studies of Davies et al. [4] and Shai et al. [34] lasted 6, 8 and 12 weeks respectively. This indicates that a longer duration of alcohol consumption may be needed to exert an effect on insulin sensitivity. Finally, the relation between moderate alcohol intake and insulin sensitivity might be influenced by sex, since the association between alcohol consumption and type 2 diabetes appears to be stronger in women than in men, as observed in some observational studies [1]. This sex difference may be explained partly by changes associated with menopause, which may mediate the relation between alcohol and triacylglycerol levels, the latter being an independent risk factor for type 2 diabetes [36]. Compared with postmenopausal non-drinkers, postmenopausal drinkers have lower triacylglycerol levels, whereas male drinkers have higher triacylglycerol levels compared with male abstainers [37].
###end p 40
###begin p 41
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 246 252 246 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 568 574 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
Intervention-associated changes in ADIPOQ mRNA in subcutaneous adipose tissue correlated with changes in plasma protein levels of total adiponectin. In line with this are cross-sectional studies [38, 39] showing associations between subcutaneous ADIPOQ mRNA levels and plasma levels of adiponectin. This finding suggests that the alcohol-induced increase in plasma adiponectin levels is mediated by de novo synthesis rather than decreased renal function [40] or post-transcriptional regulation [41]. Changes in plasma HMW adiponectin did not correlate with changes in ADIPOQ mRNA levels. However, the formation of multimer oligomers of HMW adiponectin is influenced by several post-translational modifications [42], which can account for the absence of such a correlation.
###end p 41
###begin p 42
###xml 83 85 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 128 134 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 248 254 236 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 306 311 294 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 511 516 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 720 725 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 730 736 718 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 790 795 778 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAI-1</italic>
###xml 868 870 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 873 878 861 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAI-1</italic>
###xml 923 925 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 990 996 974 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 242 247 <span type="species:ncbi:9606">human</span>
###xml 387 399 <span type="species:ncbi:9606">participants</span>
Adiponectin synthesis is under the control of the transcription factor PPAR-gamma [20]. PPAR-gamma ligands induce expression of ADIPOQ via direct binding of the PPAR-gamma/retinoid X receptor heterodimer to the PPAR-responsive element in the human ADIPOQ promoter. We indeed observed a trend for increased PPARG mRNA levels after the alcohol intervention. However, our sample size of 36 participants was anticipated to detect a 20% change in mRNA levels. As the intervention gave rise to a change of only 9% in PPARG mRNA, our study was underpowered to detect a significant difference. Besides this trend for increased PPAR levels, we also found a strong correlation between intervention-associated changes in levels of PPARG and ADIPOQ mRNAs. Furthermore, previous research has shown that PAI-1 expression and PAI-1 protein levels increase after alcohol consumption [21]. PAI-1 expression is also regulated by PPAR-gamma [22]. It thus seems plausible that moderate alcohol use might alter ADIPOQ expression and, consequently, adiponectin protein levels, also in a PPAR-gamma-mediated manner.
###end p 42
###begin p 43
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 59 62 <span type="species:ncbi:9606">men</span>
###xml 154 159 <span type="species:ncbi:9606">women</span>
Consistent with previous findings in young and middle-aged men [6, 7], we now report that total adiponectin plasma levels also increase in postmenopausal women after moderate alcohol consumption. Moreover, we found that the HMW form of plasma adiponectin also increased after 6 weeks of alcohol consumption. The increase in HMW adiponectin after moderate alcohol consumption is in line with a previous study in which a trend was observed [8]. In the present study, however, we used a more sensitive and precise method to quantify HMW adiponectin-ELISA instead of quantitative western blotting.
###end p 43
###begin p 44
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
The observed changes in insulin sensitivity as measured by HOMA-IR did not correlate with the alcohol-induced changes in total or HMW adiponectin, the latter of which is proposed to be a better predictor of insulin sensitivity [43]. These findings are consistent with other lifestyle interventions, such as weight loss [44] and exercise interventions [45], and with previous observations of our group [7, 8] which showed increased adiponectin plasma levels without changes in insulin sensitivity. In this study we did find an effect of alcohol on insulin sensitivity irrespective of changes in adiponectin levels. The present results may suggest a possible independent effect of alcohol on insulin sensitivity in addition to an adiponectin-mediated effect on insulin sensitivity.
###end p 44
###begin p 45
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
Looking at our cross-sectional data, we did observe correlations between HOMA-IR and adiponectin levels after both alcohol and placebo treatment (data not shown). This is in line with published literature in which associations between adiponectin and insulin sensitivity have been shown consistently [14-17]. Possibly, increased adiponectin levels partly explain the improved insulin sensitivity seen among moderate alcohol consumers [18, 19]. Studies have revealed that circulating adiponectin levels are inversely associated with markers of inflammation [39, 46, 47], whereas low-grade inflammation is thought to contribute to insulin resistance [48]. Therefore, adiponectin may lead to improved insulin sensitivity through effects on inflammatory markers.
###end p 45
###begin p 46
###xml 254 260 254 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADIPOQ</italic>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 174 179 <span type="species:ncbi:9606">women</span>
###xml 669 674 <span type="species:ncbi:9606">women</span>
###xml 917 923 <span type="species:ncbi:9606">people</span>
In conclusion, the results of the present study demonstrate that 6 weeks of moderate alcohol consumption improves insulin sensitivity and the lipid profile in postmenopausal women. Furthermore, moderate alcohol consumption increases subcutaneous adipose ADIPOQ mRNA levels and plasma levels of adiponectin. This suggests that the alcohol-induced increase in adiponectin is attributable, at least in part, to transcriptional alterations in adipose tissue. The observed improvements in insulin sensitivity, lipid profile and adiponectin levels when consuming 2.5 standard drinks per day may reduce the risk of type 2 diabetes and cardiovascular disease in postmenopausal women. Despite these potentially beneficial findings, the scientific literature indicates that alcohol drinking may also have detrimental effects on health [49]. Both potential benefits and risks should be taken into consideration when counselling people about consumption.
###end p 46
###begin title 47
Acknowledgements
###end title 47
###begin p 48
We thank all those involved in the conduct of the study for their efforts. The research described in this article was partly funded by the Dutch Foundation for Alcohol Research (SAR).
###end p 48
###begin p 49
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
###end p 49
###begin p 50
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution-Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 50
###begin title 51
References
###end title 51
###begin article-title 52
Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies
###end article-title 52
###begin article-title 53
###xml 60 65 <span type="species:ncbi:9606">women</span>
alcohol consumption and risk of type 2 diabetes among older women
###end article-title 53
###begin article-title 54
Moderate alcohol consumption and insulin sensitivity: observations and possible mechanisms
###end article-title 54
###begin article-title 55
###xml 123 128 <span type="species:ncbi:9606">women</span>
Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial
###end article-title 55
###begin article-title 56
###xml 55 58 <span type="species:ncbi:9606">men</span>
The effect of alcohol intake on insulin sensitivity in men: a randomized controlled trial
###end article-title 56
###begin article-title 57
Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity
###end article-title 57
###begin article-title 58
###xml 101 106 <span type="species:ncbi:9606">human</span>
The effect of moderate alcohol consumption on adiponectin oligomers and muscle oxidative capacity: a human intervention study
###end article-title 58
###begin article-title 59
Influence of moderate daily wine consumption on body weight regulation and metabolism in healthy free-living males
###end article-title 59
###begin article-title 60
###xml 125 130 <span type="species:ncbi:9606">women</span>
Influence of moderate chronic wine consumption on insulin sensitivity and other correlates of syndrome X in moderately obese women
###end article-title 60
###begin article-title 61
The effect of moderate alcohol consumption on fat distribution and adipocytokines
###end article-title 61
###begin article-title 62
###xml 108 111 <span type="species:ncbi:9606">men</span>
Effect of tequila on homocysteine, insulin secretion, insulin sensitivity, and metabolic profile in healthy men
###end article-title 62
###begin article-title 63
Adiponectin: more than just another fat cell hormone?
###end article-title 63
###begin article-title 64
Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism
###end article-title 64
###begin article-title 65
###xml 106 109 <span type="species:ncbi:9606">men</span>
###xml 114 119 <span type="species:ncbi:9606">women</span>
Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study
###end article-title 65
###begin article-title 66
Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians
###end article-title 66
###begin article-title 67
Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study
###end article-title 67
###begin article-title 68
Relationship between moderate alcohol consumption and adiponectin and insulin sensitivity in a large heterogeneous population
###end article-title 68
###begin article-title 69
###xml 112 117 <span type="species:ncbi:9606">women</span>
Alcohol consumption in relation to metabolic regulation, inflammation, and adiponectin in 64-year-old Caucasian women: a population-based study with a focus on impaired glucose regulation
###end article-title 69
###begin article-title 70
Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors
###end article-title 70
###begin article-title 71
Endothelial cell fibrinolysis: transcriptional regulation of fibrinolytic protein gene expression (t-PA, u-PA, and PAI-1) by low alcohol
###end article-title 71
###begin article-title 72
###xml 24 29 <span type="species:ncbi:9606">human</span>
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease
###end article-title 72
###begin article-title 73
Comparison between the urinary alcohol markers EtG, EtS, and GTOL/5-HIAA in a controlled drinking experiment
###end article-title 73
###begin article-title 74
Evaluation of a new immunoassay for urinary ethyl glucuronide testing
###end article-title 74
###begin article-title 75
PPARgamma activity in subcutaneous abdominal fat tissue and fat mass gain during short-term overfeeding
###end article-title 75
###begin article-title 76
###xml 89 94 <span type="species:ncbi:9606">women</span>
Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women
###end article-title 76
###begin article-title 77
###xml 116 122 <span type="species:ncbi:9606">humans</span>
Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans
###end article-title 77
###begin article-title 78
Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects
###end article-title 78
###begin article-title 79
###xml 71 76 <span type="species:ncbi:9606">women</span>
Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women
###end article-title 79
###begin article-title 80
Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status
###end article-title 80
###begin article-title 81
###xml 63 68 <span type="species:ncbi:9606">human</span>
Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone
###end article-title 81
###begin article-title 82
###xml 11 16 <span type="species:ncbi:9606">women</span>
Changes in women's plasma lipid and lipoprotein concentrations due to moderate consumption of alcohol are affected by dietary fat level
###end article-title 82
###begin article-title 83
###xml 104 109 <span type="species:ncbi:9606">women</span>
Effect of moderate alcohol consumption on parameters of reverse cholesterol transport in postmenopausal women
###end article-title 83
###begin article-title 84
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial
###end article-title 84
###begin article-title 85
###xml 52 59 <span type="species:ncbi:9606">persons</span>
Metabolic effects of alcohol in the form of wine in persons with type 2 diabetes mellitus
###end article-title 85
###begin article-title 86
Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
###end article-title 86
###begin article-title 87
###xml 130 135 <span type="species:ncbi:9606">women</span>
###xml 140 143 <span type="species:ncbi:9606">men</span>
###xml 153 158 <span type="species:ncbi:9606">Women</span>
Alcohol dehydrogenase type 1C (ADH1C) variants, alcohol consumption traits, HDL-cholesterol and risk of coronary heart disease in women and men: British Women's Heart and Health Study and Caerphilly cohorts
###end article-title 87
###begin article-title 88
###xml 28 33 <span type="species:ncbi:9606">human</span>
Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression
###end article-title 88
###begin article-title 89
###xml 71 76 <span type="species:ncbi:9606">women</span>
Association between adiponectin and mediators of inflammation in obese women
###end article-title 89
###begin article-title 90
Adiponectin and chronic kidney disease
###end article-title 90
###begin article-title 91
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression
###end article-title 91
###begin article-title 92
Post-translational modifications of adiponectin: mechanisms and functional implications
###end article-title 92
###begin article-title 93
Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome
###end article-title 93
###begin article-title 94
Changes of adiponectin oligomer composition by moderate weight reduction
###end article-title 94
###begin article-title 95
Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays
###end article-title 95
###begin article-title 96
Adiponectin as an anti-inflammatory factor
###end article-title 96
###begin article-title 97
Inflammation, stress, and diabetes
###end article-title 97
###begin title 98
Abbreviations
###end title 98
###begin p 99
ethyl glucuronide
###end p 99
###begin p 100
high molecular weight
###end p 100
###begin p 101
homeostasis model assessment of insulin resistance
###end p 101
###begin p 102
plasminogen activator inhibitor 1
###end p 102
###begin p 103
peroxisome proliferator-activated receptor
###end p 103

